Transcoronary ablation of septal hypertrophy for hypertrophic obstructive cardiomyopathy: Feasibility, clinical benefit, and short term results in elderly patients

Heart

Volumn 90, Issue 6, 2004, Pages 638-644

  Gietzen, F H ^a,b   Leuner, C J ^b   Obergassel, L ^b   Strunk Mueller, C ^b   Kuhn, H ^b  

^a Centre of Cardiovascular Medicine   (Germany)

^b OWL University   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CATHETER ABLATION; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; ENZYME ACTIVITY; EVALUATION; EXERCISE TEST; FEMALE; FOLLOW UP; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HEART MUSCLE OXYGEN CONSUMPTION; HEART SEPTUM DEFECT; HEREDITARY HYPERTENSION; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; LUNG ARTERY PRESSURE; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; PATIENT REFERRAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYNCOPE; WORKLOAD;

EID: 2442671478     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2003.017509     Document Type: Article

References (40)

1. Loogen F, Kuhn H, Gietzen F, et al. Clinical course and prognosis of patients with typical and atypical hypertrophic obstructive and with hypertrophic non-obstructive cardiomyopathy. Eur Heart J 1983;4(suppl F):145-53.
2. Maron BJ, Bonow RO, Cannon RO, et al. Hypertrophic cardiomyopathy: interrelations of clinical manifestations, pathophysiology, and therapy. N Engl J Med 1987;316:780-9, 844-52.
3. Wigle ED, Rakowski H, Kimball BP, et al. Hypertrophic cardiomyopathy: clinical spectrum and treatment. Circulation 1995;92:1680-92.
4. Spirito P, Seidmon CE, McKenna WJ, et al. The management of hypertrophic cardiomyopathy. N Engl J Med 1997;336:775-85.
5. Morrow AG, Reitz BA, Epstein SE, et al. Operative treatment in hypertrophic subaortic stenosis: techniques, and the results of pre and postoperative assessments in 83 patients. Circulation 1975;52:88-102.
6. Maron BJ, Epstein SE, Morrow AG. Symptomatic status and prognosis of patients after operation for hypertrophic obstructive cardiomyopathy: efficacy of ventricular septal myotomy and myectomy. Eur Heart J 1983;4(suppl F):175-85.
7. Schulte HD, Borisov K, Gams E, et al. Management of symptomatic hypertrophic obstructive cardiomyopathy: long-term results after surgical therapy. Thorac Cardiovasc Surg 1999;47:213-8.
8. Robbins RC, Stinson EB. Long-term results of left ventricular myotomy and myectomy for obstructive hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg 1996;111:586-94.
9. Kuhn H, Gietzen F, Leuner Ch, et al. Induction of subaortic septal ischaemia to reduce obstruction in hypertrophic obstructive cardiomyopathy: studies to develop a new catheter-based concept of treatment. Eur Heart J 1997;18:846-51.
10. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 1995;346:211-4.
11. Gietzen FH, Leuner ChJ, Raute-Kreinsen U, et al. Acute and long-term results after transcoronory ablation of septal hypertrophy (TASH): catheter interventional treatment for hypertrophic obstructive cardiomyopathy. Eur Heart J 1999;20:1342-54.
12. Kuhn H, Gietzen FH, Schäfers M, et al. Changes in the left ventricular outflow tract after transcoronary ablation of septal hypertrophy (TASH) for hypertrophic obstructive cardiomyopathy as assessed by transoesophageal echocardiography and by measuring myocardial glucose utilization and perfusion. Eur Heart J 1999;20:1808-17.
13. Knight Ch, Kurbaan AS, Seggewiss H, et al. Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy: outcome in the first series of patients. Circulation 1997;95:2075-81.
14. Faber L, Seggewiss H, Gleichmann U. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography. Circulation 1998;98:2415-21.
15. Lakkis NM, Nagueh SF, Kleimann NS, et al. Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. Circulation 1998;98:1750-5.
16. Boekstegers P, Steinbigler P, Molnar A, et al. Pressure-guided nonsurgical myocardial reduction induced by small septal infarctions in hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2001;38:846-53.
17. Mazur W, Nagueh SF, Lakkis NM, et al. Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation 2001;103:1492-6.
18. Nagueh SF, Ommen SR, Lakkis NM, et al. Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2001;38:1701-6.
19. Wigle ED, Schwartz L, Woo A, et al. To ablate or operate? That is the Question! J Am Coll Cardiol 2001;38:1707-10.
20. Fananapazir L, McAreavey D. Therapeutic options in patients with obstructive hypertrophic cardiomyopathy and severe drug-refractory symptoms. J Am Coll Cardiol 1998;31:259-64.
21. Kuhn H, Gietzen FH, Leuner Ch, et al. Transcoronary ablation of septal hypertrophy (TASH): a new treatment option for hypertrophic obstructive cardiomyopathy. Z Kardiol. 2000;89: IV/41-54.
22. Spirito P, Maron BJ. Perspectives on the role of new treatment strategies in hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 1999;33:1071-5.
23. Maron BJ. New interventions for obstructive hypertrophic cardiomyopathy: promise and prudence. Eur Heart J 1999;20:1292-4.
24. Braunwald E. Hypertrophic cardiomyopathy: the benefits of a multidisciplinary approach. N Engl J Med 2002;347:1306-7.
25. Gietzen FH, Leuner ChJ, Hegselmann J, et al. [letter]. Eur Heart J 2000;21:590-5.
26. Topol EJ, Traill TA, Fortuin NJ. Hypertensive hypertrophic cardiomyopathy of the elderly. N Engl J Med 1985;312:277-83.
27. Lever HM, Karam RF, Currie PJ, et al. Hypertrophic cardiomyopathy in the elderly: distinctions from the young based on cardiac shape. Circulation 1989;79:580-9.
28. Lewis JF, Maron BJ. Elderly patients with hypertrophic cardiomyopathy: a subset with distinctive left ventricular morphology and progressive clinical course late in life. J Am Coll Cardiol 1989;13:36-45.
29. Fay WP, Taliercio CP, Ilstrup DM, et al. Natural history of hypertrophic cardiomyopathy in the elderly. J Am Coll Cardiol 1990;16:821-6.
30. Chikamori T, Doi YL, Yonezawa Y, et al. Comparison of clinical features in patients ≥60 years of age and those ≤40 years of age with hypertrophic cardiomyopathy. Am J Cardiol 1990;66:875-8.
31. Maron BJ, Olivotto I, Spirito P, et al. Epidemiology of hypertrophic cardiomyopathy-related death revisited in a large non-referral-based patient population. Circulation 2000;102:858-64.
32. Sahn DJ, De Maria A, Kisslo J, et al. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978;58:1072-83.
33. Panza JA, Petrone RK, Fananapazir L, et al. Utility of continuous wave Doppler echocardiography in noninvasive assessment of the left ventricular outflow tract pressure gradient in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1992;19:91-9.
34. Kuhn H, Gietzen F, Leuner C. "The abrupt no-flow": a no-reflow like phenomenon in hypertrophic cardiomyopathy [letter]. Eur Heart J 2002;23:91-3.
35. Whiting RB, Powell WJ, Dinsmore RE, et al. Idiopathic hypertrophic subaortic stenosis in the elderly. N Engl J Med 1971;285:196-200.
36. Petrin TJ, Tavel ME. Idiopathic hypertrophic subaortic stenosis as observed in a large community hospital: relation to age and history of hypertension. J Am Geriatr Soc 1979;27:43-6.
37. Krasnow N, Stein RA. Hypertrophic cardiomyopathy in the aged. Am Heart J 1978;96:326-36.
38. Zieman SJ, Fortuin NJ. Hypertrophic and restrictive cardiomyopathies in the elderly. Cardiol Clin 1999;17:159-72.
39. Kitzman DW, Scholz DG, Hagen PT, et al. Age-related changes in normal human hearts during the first 10 decades of life. Part II (maturity). A quantitative anatomic study of 765 specimens from subjects 20 to 99 years old. Mayo Clin Proc 1988;63:137-46.
40. Wigle ED, Sasson Z, Henderson MA, et al. Hypertrophic cardiomyopathy: the importance of the site and the extent of hypertrophy: a review. Prog Cardiovasc Dis 1985;28:1-83.